What is PCVX's market cap?

$10.34B, based on the Nov 4 close of $65.68.

Does Vaxcyte pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PCVX is sold short?

14.6M shares, 11.2% of float, as of Oct 15, 2026.

What sector is PCVX in?

Healthcare, in the Biotechnology industry.

NASDAQ · PCVXHealthcareBiotechnology

Vaxcyte, Inc. Common Stock (PCVX)

$65.68+8.01%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$65.68▲ 58.84% in range

Nov 4, 2025Low $40.32 · High $73.82Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Vaxcyte closed at $65.68 on Nov 4, up 8.01%, 11.0% below its 52-week closing high. Volume of 2.3M shares was 0.77× its 20-day average (below normal).

Split-adjusted performance: -1.5% over one month, +15.0% over six months, +53.4% over one year.

Short interest was 14.6M shares at the Oct 15 settlement, down 15.4% from the prior report (11.2% of float, 2.9 days to cover).

Market cap$10.34B157.4M shares

Revenue · quarter$0.00—

Diluted EPS$-1.97—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range40.32 – 73.82−11.0% from high

Volume2.3M0.77× 20-day avg

Volatility · 60d72.2%Annualised

Short % of float11.2%2.9 days to cover

Net cash$1.49BCash $1.49B

Next earnings—Not scheduled

Split-adjusted performance

1W +6.9%1M −1.5%3M +11.5%6M +15.0%YTD +42.3%1Y +53.4%3Y +38.0%5Y +198.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum77

Revenue growth—

Net margin—

Value (low P/E)—

Size92

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short14.6M−15.4% vs prior

Days to cover2.9Settled Oct 15

% of float11.2%

Short vol. 10d78.4%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PCVXVaxcyte	$65.68	+8.01%	+15.0%	—	—	—	$10.34B
IBRXImmunityBio	$8.93	+7.72%	+6.6%	+93.9%	−449.6%	—	$9.46B	Compare
TWSTTwist Bioscience	$142.58	+1.63%	+139.5%	+23.2%	−29.6%	—	$9.45B	Compare
RGENRepligen	$178.20	−0.04%	+41.7%	+10.9%	−18.4%	—	$11.31B	Compare
TECHBio-Techne	$72.73	+0.10%	+53.4%	+1.3%	17.0%	62.8	$11.42B	Compare
KRYSKrystal Biotech	$310.84	+1.90%	+7.6%	+30.2%	49.5%	40.9	$9.20B	Compare
KYMRKymera Therapeutics	$136.25	+7.21%	+58.0%	−100.0%	—	—	$11.63B	Compare
HALOHalozyme Therapeutics	$130.34	+1.34%	+96.4%	+47.7%	47.8%	35.8	$14.79B	Compare
NBIXNeurocrine Biosciences	$166.05	+0.73%	+12.9%	+41.2%	18.4%	24.0	$16.88B	Compare

News about Vaxcyte

All news →

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?Zacks Investment Research · 5d ago▲ Positive Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a BetZacks Investment Research · Oct 14, 2026▲ Positive Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesGlobeNewswire Inc. · Oct 7, 2026▲ Positive The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteZacks Investment Research · Sep 23, 2026Neutral Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the FirmThe Motley Fool · Sep 8, 2026Neutral

Quick answers

What does Vaxcyte do?: Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications.
What is PCVX's market cap?: $10.34B, based on the Nov 4 close of $65.68.
Does Vaxcyte pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PCVX is sold short?: 14.6M shares, 11.2% of float, as of Oct 15, 2026.
What sector is PCVX in?: Healthcare, in the Biotechnology industry.

About Vaxcyte

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

HQ: San Carlos, CA507 employeesListed Jun 12, 2020vaxcyte.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology